The Committee to Restore Nymox Shareholder Value Issues Notice of Special Meeting of Nymox Pharmaceutical Shareholders

CARSON CITY, Nev. & LONDON--(BUSINESS WIRE)--The Committee to Restore Nymox Shareholder Value, Inc. (CRNSV), with a goal to recover shareholder value in Nymox Pharmaceutical Corporation (NYMX-F) (the “Company” or “Nymox”), today announced that pursuant to the October 5, 2023 Order of Court in Bahamas Supreme Court (the “Court”) Action No. 2023/Com/com/00057 (the “Order”), it has issued notice of the special meeting of Nymox shareholders (the “Notice”) to be held at Margaritaville Beach Resort, 2 Bay St., Nassau, Bahamas, at 9 a.m. (EST) on November 8, 2023 (the “Special Meeting”). As set forth in the Notice, CRNSV is calling the Special Meeting for the purpose of approving proposals to significantly improve the Company’s leadership and governance, including proposals relating to the termination of Dr. Paul Averback as President and Chief Executive Officer of the Company and reconstitution of the Nymox Board of Directors (the “Board”) through the removal of each incumbent Board member and appointment of five highly qualified nominees as directors of the Company.

The Court ordered the Company to give notice of the convening of a shareholder meeting by October 9, 2023 to be held no later than 28 days from such notice and if Nymox fails to do so, the Order empowers CRNSV to give notice of the shareholder meeting itself. CRNSV is therefore providing Notice of the Special Meeting given the Company’s failure to do so within the requisite deadline provided in the Order. Importantly, the Order presents shareholders with a critical opportunity to right the ship at Nymox, but it is ultimately up to us, the shareholders, to take action and seize this vital opportunity at the upcoming Special Meeting. CRNSV looks forward to sharing further details regarding the Special Meeting and the proposals to be presented at such Special Meeting.

The full text of the Notice is provided below:

NYMOX PHARMACEUTICAL CORPORATION
(COMPANY NO. 175894B)
Pursuant to the International Business Companies Act, Ch. 309, Statute Laws of the Bahamas

TO: Shareholders of Nymox Pharmaceutical Corporation (“Nymox” or the “Company”):

Notice is hereby given that pursuant to the October 5, 2023 Order of Court in Bahamas Supreme Court (the “Court”) Action No. 2023/Com/com/00057, a Special Meeting of the Shareholders of Nymox is being called by the Committee to Restore Nymox Shareholder Value, Inc. (“CRNSV”) to be held at Margaritaville Beach Resort, 2 Bay St., Nassau, Bahamas, at 9 a.m. (EST) on November 8, 2023 (the “Special Meeting”) for the purpose of approving proposals to significantly improve the Company’s leadership and governance, including proposals relating to the termination of Dr. Paul Averback as President and Chief Executive Officer of the Company and reconstitution of the Nymox Board of Directors (the “Board”) through the removal of each incumbent Board member and appointment of five highly-qualified nominees as directors of the Company.

CRNSV intends to provide further details regarding the Special Meeting and the proposals to be presented at such Special Meeting and will be disseminating relevant materials to shareholders in furtherance thereof.

All long-suffering Nymox shareholders, regardless of the size of their holdings, are invited to join the rapidly growing coalition by visiting the fully dedicated website https://crnsv.com/ reviewing all the relevant information and signing up for further updates, this will be a key communication platform as we move into the solicitation process. There is no obligation to join or support required and all personal contact information and identification will be confidential and protected. CRNSV will contact each shareholder to confirm participation and support for the changes called for in Nymox.

Thank you for your support,

/s/ Randall Lanham

Randall Lanham, on behalf of CRNSV

About The Committee to Restore Nymox Shareholder Value, Inc. (CRNSV)

CRNSV was formed by former executives of the NYMOX PHARMACEUTICAL CORP ("NYMX-F") with a goal to restore shareholder value in NYMOX (the Company). With a commitment to overcome the steep decline and volatility of the stock price following the catastrophic NASDAQ Delisting Decision, CRNSV has issued rebuttal letters to all Company shareholders and continues to emphasize lack of Company leadership, inability to realize the potential for valuable and promising results through a relationship with a highly respected global healthcare and specialty pharmacy solutions company with expertise to help commercialize the Company’s Benign Prostatic Hyperplasia (BPH) product, and Nymox’s lack of solution or plan for financial recovery of shareholder value. Headquartered in Carson City, Nevada with offices in London, CRNSV documents are available at https://www.crnsv.com/.

Chris Riley
info@crnsv.com